Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Flavopiridol is a broad cyclin-dependent kinase inhibitor (CDKI) that induces apoptosis of malignant lymphocytes in vitro and in murine lymphoma models. We conducted a phase I dose-escalation study to determine the maximum tolerated dose (MTD) for single-agent flavopiridol administered on a pharmaco...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jones, Jeffrey A., Rupert, Amy S., Poi, Ming, Phelps, Mitch A., Andritsos, Leslie, Baiocchi, Robert, Benson, Don M., Blum, Kristie A., Christian, Beth, Flynn, Joseph, Penza, Sam, Porcu, Pierluigi, Grever, Michael R., Byrd, John C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4150545/
https://ncbi.nlm.nih.gov/pubmed/23959599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23568
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge